Estimated read time: 4-5 minutes
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.
[STK] NYSE:DVA
[IN] HEA MTC PHA
[SU]
-- WITH PHOTO -- TO HEALTH, AND NATIONAL EDITORS:
DaVita Clinical Research Presents Research Results at the American
Nephrology Nurses Association National Symposium
ANAHEIM, Calif., April 14, 2014 /PRNewswire-USNewswire/ -- DaVita
Clinical Research (DCR) (NYSE: DVA), a specialty contract research
organization with services spanning the full spectrum of drug and
device development, today announced that company representatives will
present four abstracts at the American Nephrology Nurses Association
(ANNA) 45th National Symposium scheduled for April 13-16, 2014 in
Anaheim, Calif.
ANNA is designed to provide an educational and networking environment
for nephrology nurses and practice administrators to expand knowledge,
enhance clinical skills, and translate evidence into daily practice.
"At DaVita, we're committed to improving the care of patients with
renal disease by focusing on translational research," said Mahesh
Krishnan, M.D., M.P.H., M.B.A., F.A.S.N., vice president clinical
innovation and public policy at DaVita. "Presenting our research
initiatives here at ANNA creates an ideal platform to translate those
findings into clinical care for kidney patients."
Researchers from DaVita, the dialysis division of DaVita Healthcare
Partners Inc., and DCR will present results from a number of
innovative clinical improvement programs originating from DaVita and
its research partners. DCR seeks to advance the future of medicine,
the practice of medicine and to innovate through personalized
medicine. DCR and DaVita share a dedication to improving the health
and quality of life for kidney care patients.
DaVita will focus on meaningful research initiatives in end-stage
renal disease, including:
-- "Choice of Drain Systems and Associated Peritonitis Rates in
Automated Peritoneal Dialysis Patients," oral presentation by Michelle
Cassin, R.N., C.P.D.N. on Monday, April 14 in Abstract Concurrent
Session #162, from 5:35 p.m.-5:55 p.m.
-- "Hemodialysis Session Length Has a Dose Relationship With Hazard
Rates of Cause-Specific Hospitalization and Mortality," oral
presentation by Irina Goykhman, R.N., B.S.N., M.B.A. on Monday, April
14 in Abstract Concurrent Session #161, from 4:20 p.m.- 4:40 p.m.
-- "A Pilot Quality Improvement Program to Minimize Catheter-Related
Bloodstream Infection in an Outpatient Hemodialysis Setting," poster
presentation by Nancy Culkin, B.S.N., R.N., C.N.N.
-- "A Standardized Algorithm for Peritonitis Surveillance," poster
presentation by Michelle Cassin, R.N., C.P.D.N.
Poster presentations will be held Monday, April 14, 2:45 p.m.-4:15
p.m. and Tuesday, April 15, 9:00 a.m.-10:15 a.m.
DaVita, DaVita Clinical Research, and DCR are trademarks or registered
trademarks of DaVita Healthcare Partners Inc.
About DaVita DaVita is the dialysis division of DaVita HealthCare
Partners Inc., a Fortune 500@ company that, through its operating
divisions, provides a variety of health care services to patient
populations throughout the United States and abroad. A leading
provider of kidney care in the United States, DaVita delivers dialysis
services to patients with chronic kidney failure and end stage renal
disease. DaVita strives to improve patients' quality of life by
innovating clinical care, and by offering integrated treatment plans,
personalized care teams and convenient health-management services. As
of Dec. 31, 2013, DaVita operated or provided administrative services
at 2,074 outpatient dialysis centers located in the United States
serving approximately 163,000 patients. The company also operated 73
outpatient dialysis centers located in ten countries outside the
United States. DaVita supports numerous programs dedicated to creating
positive, sustainable change in communities around the world. The
company's leadership development initiatives and social responsibility
efforts have been recognized by Fortune, Modern Healthcare, Newsweek
and WorldBlu. For more information, please visit DaVita.com.
About DaVita Clinical Research DaVita Clinical Research (DCR), a
wholly owned subsidiary of DaVita HealthCare Partners Inc. (NYSE:
DVA), uses its extensive, applied database and real-world healthcare
experience to assist pharmaceutical and medical device companies in
the design, recruitment and completion of retrospective, prospective
pragmatic and clinical trials. DCR's scientific and clinical expertise
spans the lifecycle of product development with more than 150 client
companies. DCR's Biorepository, Early Clinical Research unit (Phase
I-IIa) and Clinical Development (Phase IIb through post-marketing)
network of physicians and investigative sites, data research, Health
Economics & Outcomes Research, and Medical Communications are focused
on providing world-class research in both complex/specialty
populations and therapeutic areas, and especially in CKD and ESRD
populations. To learn more about DCR, visit
www.davitaclinicalresearch.com.
Logo - http://photos.prnewswire.com/prnh/20140212/DC63568LOGO
Contact Information Media: Bianca Violante Office: (303) 876-661
Mobile: (443) 417-6044 Bianca.Violante@DaVita.com
SOURCE DaVita Clinical Research
-0- 04/14/2014
/Photo: http://photos.prnewswire.com/prnh/20140212/DC63568LOGO
(NYSE:DVA) /
CO: DaVita Clinical Research
ST: California
IN: HEA MTC PHA
PRN
-- DC04086 --
0000 04/14/2014 10:12:00 EDT http://www.prnewswire.com
Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
